key: cord-0855767-m00cjv78 authors: Hilmer, Sarah N.; Petrovic, Mirko; Le Couteur, David G.; Schwartz, Janice B.; Thuermann, Petra title: Development, evaluation and use of COVID‐19 vaccines in older adults: Preliminary principles for the pandemic and beyond date: 2021-08-02 journal: Br J Clin Pharmacol DOI: 10.1111/bcp.14967 sha: d6b096d94aa9dbf0400e2309cb0dddb031f578fa doc_id: 855767 cord_uid: m00cjv78 nan The COVID-19 pandemic brought development, evaluation and use of vaccines for older adults into the spotlight. Here, we reflect on the gaps that were highlighted and strategies to fill them, during the pandemic and beyond. This commentary draws on principles we compiled through the geriatric pharmacology subcommittee of the clinical division of the International Union of Basic and Clinical Pharmacology (IUPHAR), to guide the regulation and use of the COVID-19 vaccines for older adults. 1 These are based on principles for evaluation and use of other therapeutics in older people. During a pandemic, regulatory and clinical decisions may need to be made rapidly and sometimes in the absence of clinical data from all at risk subsets of the population. In adults aged over 65 years, there is a wide range of physiological and pharmacological variability that needs to be considered. The increase in morbidity and mortality seen in older adults with COVID-19 is comparable to that seen with other conditions, 2 probably related to underlying biological mechanisms of ageing, physiological factors such as altered immunity, frailty (loss of physiologic reserve), altered presentation of infection, pre-existing multimorbidity, polypharmacy and nutritional deficits. 3 How these factors affect the safety or efficacy of a new drug or vaccine is not well understood. Outcomes of COVID-19 vaccines prioritised by older patients may include less severe disease, avoiding the need for hospitalisation and potentially reducing the functional impairment often seen after severe infections in older people. Public health, in turn, may prioritise reduced transmission among older adults, particularly for those in residential aged care facilities. Clinically, competing risks for morbidity and mortality must be considered when deciding on vaccinations and other treatments. For people in the last weeks or months of life, enduring the side effects of a vaccine may not seem worthwhile, since the vaccine in such cases is unlikely to reduce hospitalisation or extend life. However, patient experiences of hospitalisation and mortality may differ when these events are caused by COVID-19, which often causes severe dyspnoea, isolation and delirium, compared to when they result from sudden vascular events or slower degenerative disease. Moreover, vaccination may allow for more social contacts with family, friends and/or professional caregivers, and thus be of particular importance during the last weeks or months of life. Here, we outline key considerations for evaluation and use of COVID-19 vaccines in older adults and reflect on their current and potential future implementation. This includes assessment of preclinical data in aged animals and clinical data in older adults, judicious extrapolation from relevant data in younger age groups or from comparable interventions, and planning pharmacovigilance. Ideally, direct data from preclinical models and clinical trial participants representative of the population who will use the vaccine would be available for regulatory evaluation. Preclinical data should include evaluation in aged animals to understand the effects of ageing physiology and comorbidities on immune response, efficacy and safety. Animal models that are relevant to humans are required, including models of ageing, multimorbidity and frailty. 4 Assessment of vaccine efficacy in such models must consider susceptibility to infection as well as clinically relevant measures of response. 5 There is a need for access to colonies of aged animals to rapidly assess effects of new treatments in old age. At every phase, clinical trials should adequately represent older adults across the older age span in proportion to the numbers having a condition or at risk for the disease or having severe outcomes. This may include analysis of subgroups by chronologic age (65-74, 75-84 and >85 years) and of people with frailty, multimorbidity and polypharmacy. There have been deliberate efforts to study COVID-19 vaccine efficacy and safety in different age groups. However, delays in obtaining data from older participants delayed regulatory approval of some vaccines for older adults and even resulted in contradictory recommendations by different authorities. (coincidental). Future work could develop and validate case finding and causality assessments for older adults. Epidemiologic analyses to detect changes in prevalence of these multifactorial outcomes need to consider the timing of the events relative to vaccination, since prevalence over a longer period (e.g., 1 year) may not be sensitive to change. In clinical decision-making about use of vaccines, it is important to consider the goals and experience of the older person. Age is only one of many factors that informs clinical decision making for populations and individuals. Shared decision-making guides for frail older people have been disseminated in some jurisdictions. 12 Such tools, informed by robust data from clinical trials and pharmacovigilance in frail older people, will help optimise use and outcomes of vaccines. No funding was received to support this commentary. Geriatric Subcommittee of the Clinical Division of IUPHAR (International Union of Basic and Clinical Pharmacology) A geroscience perspective on COVID-19 mortality What is the relationship between validated frailty scores and mortality for adults with COVID-19 in acute hospital care? A systematic review Animal models of frailty: current applications in clinical research Animal and translational models of SARS-CoV-2 infection and COVID-19 Correlates of vaccine-induced protection against SARS-CoV-2. Vaccines (Basel) Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 B and T cell immune responses elicited by the BNT162b2 (Pfizer-BioNTech) 1 COVID-19 vaccine in nursing home residents Vaccines for older adults Interim case definition of thrombosis with thrombocytopenia. v9.2 Assessment of an Adverse Event Following Immunisation (AEFI) Development, evaluation and use of COVID-19 vaccines in older adults: Preliminary principles for the pandemic and beyond The authors have no conflicts of interest relevant to this manuscript.